Annual General Meeting

Management Update

2026-06-25

RESVERLOGIX

Forward Looking Statement

This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors. The forward-looking statements contained herein are expressly qualified by this cautionary statement and are made as of the date hereof. The Companies disclaim any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Donald McCaffrey
1 403 690 8887
don@resverlogix.com

RESVERLOGIX

Introduction to Resverlogix

	Resverlogix
Founded	2001
Headquarters	Calgary, Canada
Ownership	Publicly-traded (TSX:RVX)
Focus Area	Cardiometabolic
Key Leadership	Donald McCaffrey, President & CEO
	Brad Cann, CFO
	Dr. Ewelina Kulikowski, CSO
Capital Raised	>$500M
Lead Compound	Apabetalone (Phase 3)

Focus Area: Cardiovascular Disease

- Apabetalone **works in concert** with Standard of care (SoC) cardiovascular and **diabetic drugs**
  (GLP-1 RA, SGLT2i, DPP4i, statins, ACEi, ARBs, insulin, & more)
- **Cardioprotective benefits**, including reducing heart failure, observed **beyond SoC**
- Supplementary bioavailability study completed in **renally-impaired/dialysis** patients
- Strong potential for **expanding indications**

Apabetalone's clinical development programs are **well aligned** with pharma's **therapeutic focus areas**

RESVERLOGIX

Resverlogix's Lead Candidate – Apabetalone

- Orally-available, selective BET inhibitor
- Well-tolerated – clear safety record with chronic administration
- Demonstrated cardio-protective benefits – BETonMACE (Phase 3)
- Synergistic benefits in combination with SGLT2i
- Enhanced efficacy in renally-impaired subpopulation

Priority Indications

- Phase 3 – Heart Failure w/ Diabetes
- Phase 2 – Post COVID Conditions

- Robust Intellectual Property Protection (**to 2041**)
- **FDA** Breakthrough Therapy Designation
- 40+ peer-reviewed publications (incl. **Cell, Nature**)
- **4200+ patient-years** of FDA-reviewed safety data
- Detailed **proteomic & transcriptomic** analyses

RESVERLOGIX

COVID-19:

Apabetalone and Disease Progression



RESVERLOGIX

COVID-19:

Apabetalone and Disease Progression



RESVERLOGIX

Post COVID-19 Condition and Prevention of Cardiovascular Outcomes Overlap: Increased Burden of Multiple Cardiovascular Events



People who contract COVID-19 have **a 50%-70% greater risk** of severe cardiac events in the first year after their infection than people who never contracted COVID-19

Adapted from: Xie et al. 2022 (Nature Medicine)

MACE is a composite endpoint of myocardial infarction, stroke, and cardiovascular death

RESVERLOGIX

Active Apabetalone Long Covid Study

- **Recruitment completed**
- Enrollment target reduced from **200 → 150**
  - Examination of baseline data showed **statistical power would be met** with reduced enrollment
  - Final **enrollment expected to be 150-160**, with a few patients still in screening

Key Milestones

May **2026**	Full Enrollment (completed)
September **2026**	Last Patient, Last Visit (estimated)



Jordan – 2 sites
- Abdali Hospital, Amman
- Istiklal Hospital, Amman

United Arab Emirates – 2 Sites
- Al Kuwait Hospital, Dubai
- ADHRC, Abu Dhabi

Kingdom of Saudi Arabia – 2 Sites
- King Abdulaziz Hospital, Al-Ahsa
- King Abdulaziz Hospital, Riyadh

RESVERLOGIX

Clinical Outcome Measures
World Health Organization (WHO) – newest standard

Patient **A**cceptable **S**ymptom **S**tate (PASS)

Patients are asked the following:

"Taking into account all your symptoms in daily life and your functional impairment, do you consider that your current state is satisfactory?"

Values: "Yes" or "No"

Time Course: Baseline and 90 days

Long **C**ovid **I**mpact **T**ool (LCIT)

Rate the impact of your illness on:

• Personal activities	/10
• Family life	/10
• Professional life	/10
• Social life	/10
• Morale/mood	/10
• Relationship with caregivers	/10
	/60

Values: Score 0-60 (0 = no impact, 60 = max impact)

Time Course: Baseline and 90 days

RESVERLOGIX

Biomarker Data - Strong Potential for New Insights



Data Safety Monitoring Board Affirms Safety

DSMB convened **3 times** to review safety data

Each time **agreed to proceed** according to protocol

No new safety issues were identified

No cases of patients discontinuing study due to liver function tests and no cases of ALT >5x upper limit of normal

Rate of elevated liver tests were **<½ of those seen in BETonMACE** (2.7% vs 6.4%)

Rates of **serious adverse events (SAE) were lower** than in BETonMACE

Shorter study duration and **less at-risk population** likely contributed to lower SAE rate

RESVERLOGIX

Preliminary findings based on available and reviewed safety data (June 2026)

BETonMACE2 Preparations

- Detailed trial design **discussed with regulators**
- Key aspects have been decided
  - Primary endpoint to include **MACE + hospitalizations due to heart failure**
  - Background **SGLT2i for all** participants
  - Interim analysis after **~300 events** with stopping rule in place
- Decentralized monitoring is being explored to **reduce number of centers and costs**



BETonMACE2 will be larger, include 100% SGLT2i population, and a higher proportion of CKD patients

RESVERLOGIX

Financing Concept – Zenith + Resverlogix



- ~50% of the M&A proceeds will be **reinvested** in apabetalone's clinical development to fuel **long-term value creation** for both Resverlogix and ZCC
- Right of first refusal promotes **long-term partnership** with acquiring pharma

Contact

Donald McCaffrey | President & CEO
1 403 690 8887
don@resverlogix.com

RESVERLOGIX